Trial Profile
A Phase 1 Study to Investigate Bivalent Norovirus Vaccine
Planning
Phase of Trial:
Phase I
Latest Information Update: 10 Dec 2018
At a glance
- Drugs Norovirus Vaccine-Vaxart (Primary)
- Indications Norovirus infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Vaxart
- 10 Dec 2018 New trial record
- 09 Nov 2018 According to a Vaxart media release, due to a manufacturing issue, the norovirus GI.1 vaccine tablets failed release testing and the company now expect to initiate this phase I bivalent study in the first half of 2019.Vaxart is working diligently to resolve the issue.